Short-course chemotherapy for isoniazid-resistant pulmonary tuberculosis

Kuan Jen Bai, Ming Chih Yu, Jen Suo, Chen Yuan Chiang, I. Hsin Chiang, Tao Ping Lin, Kwen Tay Luh

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Standard short-course chemotherapy including isoniazid, rifampicin, pyrazinamide, and ethambutol has been the recommended treatment for tuberculosis in Taiwan since November 1990. The effectiveness of this treatment was evaluated retrospectively in 108 patients with isolates resistant to isoniazid alone and 115 patients with drug-susceptible pulmonary tuberculosis diagnosed and treated at the Taiwan Provincial Chronic Disease Control Bureau from November 1990 through December 1995. The success rate of treatment was 94.4% in patients with isoniazid-resistant Mycobacterium tuberculosis strains, which was not significantly different from the 97.4% rate in patients with susceptible strains. Of the patients treated successfully, no bacteriologic relapse was found in 97 patients with isoniazid-resistant strains or 103 patients with drug-susceptible strains 12 months after the end of chemotherapy. No significant advantage in treatment outcome was found in patients infected with isoniazid-resistant strains who received chemotherapy for more than 6 months (successful treatment rate, 95.0% vs 92.8%), but the failure rate was higher in patients with a previous history of antituberculosis therapy (17.6% vs 3.3%). We conclude that short- course chemotherapy is effective for isoniazid-resistant pulmonary tuberculosis and that there is no significant difference in treatment outcome between patients with or without isoniazid-resistant disease.

Original languageEnglish
Pages (from-to)278-282
Number of pages5
JournalJournal of the Formosan Medical Association = Taiwan yi zhi
Volume97
Issue number4
Publication statusPublished - Apr 1998
Externally publishedYes

Fingerprint

Isoniazid
Pulmonary Tuberculosis
Drug Therapy
Taiwan
Pyrazinamide
Ethambutol
Therapeutics
Rifampin
Mycobacterium tuberculosis
Pharmaceutical Preparations
Tuberculosis
Chronic Disease
Recurrence

Keywords

  • Isoniazid-resistant pulmonary tuberculosis
  • Mycobacterium tuberculosis
  • Short-course chemotherapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Short-course chemotherapy for isoniazid-resistant pulmonary tuberculosis. / Bai, Kuan Jen; Yu, Ming Chih; Suo, Jen; Chiang, Chen Yuan; Chiang, I. Hsin; Lin, Tao Ping; Luh, Kwen Tay.

In: Journal of the Formosan Medical Association = Taiwan yi zhi, Vol. 97, No. 4, 04.1998, p. 278-282.

Research output: Contribution to journalArticle

@article{60b1da189e95449faac7604b9716041a,
title = "Short-course chemotherapy for isoniazid-resistant pulmonary tuberculosis",
abstract = "Standard short-course chemotherapy including isoniazid, rifampicin, pyrazinamide, and ethambutol has been the recommended treatment for tuberculosis in Taiwan since November 1990. The effectiveness of this treatment was evaluated retrospectively in 108 patients with isolates resistant to isoniazid alone and 115 patients with drug-susceptible pulmonary tuberculosis diagnosed and treated at the Taiwan Provincial Chronic Disease Control Bureau from November 1990 through December 1995. The success rate of treatment was 94.4{\%} in patients with isoniazid-resistant Mycobacterium tuberculosis strains, which was not significantly different from the 97.4{\%} rate in patients with susceptible strains. Of the patients treated successfully, no bacteriologic relapse was found in 97 patients with isoniazid-resistant strains or 103 patients with drug-susceptible strains 12 months after the end of chemotherapy. No significant advantage in treatment outcome was found in patients infected with isoniazid-resistant strains who received chemotherapy for more than 6 months (successful treatment rate, 95.0{\%} vs 92.8{\%}), but the failure rate was higher in patients with a previous history of antituberculosis therapy (17.6{\%} vs 3.3{\%}). We conclude that short- course chemotherapy is effective for isoniazid-resistant pulmonary tuberculosis and that there is no significant difference in treatment outcome between patients with or without isoniazid-resistant disease.",
keywords = "Isoniazid-resistant pulmonary tuberculosis, Mycobacterium tuberculosis, Short-course chemotherapy",
author = "Bai, {Kuan Jen} and Yu, {Ming Chih} and Jen Suo and Chiang, {Chen Yuan} and Chiang, {I. Hsin} and Lin, {Tao Ping} and Luh, {Kwen Tay}",
year = "1998",
month = "4",
language = "English",
volume = "97",
pages = "278--282",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Elsevier Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Short-course chemotherapy for isoniazid-resistant pulmonary tuberculosis

AU - Bai, Kuan Jen

AU - Yu, Ming Chih

AU - Suo, Jen

AU - Chiang, Chen Yuan

AU - Chiang, I. Hsin

AU - Lin, Tao Ping

AU - Luh, Kwen Tay

PY - 1998/4

Y1 - 1998/4

N2 - Standard short-course chemotherapy including isoniazid, rifampicin, pyrazinamide, and ethambutol has been the recommended treatment for tuberculosis in Taiwan since November 1990. The effectiveness of this treatment was evaluated retrospectively in 108 patients with isolates resistant to isoniazid alone and 115 patients with drug-susceptible pulmonary tuberculosis diagnosed and treated at the Taiwan Provincial Chronic Disease Control Bureau from November 1990 through December 1995. The success rate of treatment was 94.4% in patients with isoniazid-resistant Mycobacterium tuberculosis strains, which was not significantly different from the 97.4% rate in patients with susceptible strains. Of the patients treated successfully, no bacteriologic relapse was found in 97 patients with isoniazid-resistant strains or 103 patients with drug-susceptible strains 12 months after the end of chemotherapy. No significant advantage in treatment outcome was found in patients infected with isoniazid-resistant strains who received chemotherapy for more than 6 months (successful treatment rate, 95.0% vs 92.8%), but the failure rate was higher in patients with a previous history of antituberculosis therapy (17.6% vs 3.3%). We conclude that short- course chemotherapy is effective for isoniazid-resistant pulmonary tuberculosis and that there is no significant difference in treatment outcome between patients with or without isoniazid-resistant disease.

AB - Standard short-course chemotherapy including isoniazid, rifampicin, pyrazinamide, and ethambutol has been the recommended treatment for tuberculosis in Taiwan since November 1990. The effectiveness of this treatment was evaluated retrospectively in 108 patients with isolates resistant to isoniazid alone and 115 patients with drug-susceptible pulmonary tuberculosis diagnosed and treated at the Taiwan Provincial Chronic Disease Control Bureau from November 1990 through December 1995. The success rate of treatment was 94.4% in patients with isoniazid-resistant Mycobacterium tuberculosis strains, which was not significantly different from the 97.4% rate in patients with susceptible strains. Of the patients treated successfully, no bacteriologic relapse was found in 97 patients with isoniazid-resistant strains or 103 patients with drug-susceptible strains 12 months after the end of chemotherapy. No significant advantage in treatment outcome was found in patients infected with isoniazid-resistant strains who received chemotherapy for more than 6 months (successful treatment rate, 95.0% vs 92.8%), but the failure rate was higher in patients with a previous history of antituberculosis therapy (17.6% vs 3.3%). We conclude that short- course chemotherapy is effective for isoniazid-resistant pulmonary tuberculosis and that there is no significant difference in treatment outcome between patients with or without isoniazid-resistant disease.

KW - Isoniazid-resistant pulmonary tuberculosis

KW - Mycobacterium tuberculosis

KW - Short-course chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0031945305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031945305&partnerID=8YFLogxK

M3 - Article

VL - 97

SP - 278

EP - 282

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

IS - 4

ER -